Esteban Rodrigo Imedio

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Suzanne F. Jones, D. Spigel, G. Falchook, 2019, Journal of Clinical Oncology.

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Suzanne F. Jones, A. Oza, J. Cragun, 2019, Journal of Clinical Oncology.